Supporting Diagnostic Innovation
Breast Cancer Genomic Testing
EndoPredict® CE-IVD
Breast Cancer Prognostic Test
A prognostic and predictive test to guide therapeutic decisions
In the breast cancer ER+, HER2-, N0 and N+
Prostate Cancer Genomic Testing
Prolaris® CE-IVD
Prostate Cancer Prognostic Test
A gene expression test that allows to stratify the risk of patients in relation to the aggressiveness of the prostate cancer
Prostate Genomic Test
Prolaris® CE-IVD
Prostate Cancer Prognostic Test
A gene expression test that allows to stratify the risk of patients in relation to the aggressiveness of the prostate cancer
Cancer of Unknown/Uncertain Primary (CUP)
Canhelp®-Origin CE-IVD
Diagnostic Test for Identifying the Origin of the Tumor
A gene expression diagnostic test that helps identify the origin of metastatic tumor by distinguishing between 21 tumor types (90% of all solid tumors)
Bladder Cancer
Canhelp®-UriBLAD CE-IVD
Diagnostic Test for Early Identification and Surveillance of Bladder Cancer Recurrence
A diagnostic gene expression test that, in combination with artificial intelligence, helps identify non-invasive bladder cancer
Bladder Cancer
Canhelp®-UriBLAD CE-IVD
Diagnostic Test for Early Identification and Surveillance of Bladder Cancer Recurrence
A diagnostic gene expression test that, in combination with artificial intelligence, helps identify non-invasive bladder cancer
HRD Test
MyChoice® CDx Plus CE-IVD
Companion Diagnostic Test for Ovarian Cancer
The test HRD of Myriad Genetics to guide therapy of ovarian cancer
with PARP inhibitors
Hereditary tumors
MyRisk® Plus CE-IVD
Hereditary Cancer Test
A multi-gene panel which helps determine the patient's risk by evaluating some hereditary tumor syndromes, referred to 11 main tumor sites
Hereditary tumors
MyRisk® Plus CE-IVD
Hereditary Cancer Test
A multi-gene panel which helps determine the patient's risk by evaluating some hereditary tumor syndromes, referred to 11 main tumor sites
Microbiota Test – Immunotherapy
BiomeOne® CE-IVD
Microbiota Test – Oncology Immunotherapy Response
The world's first microbiota-based test for predicting response to cancer immunotherapy
For information
Telephone
+39 0239261913
info@quimark.com
The content of this website is informative about the Quimark company and its products and services,
It is not intended as professional medical or health advice.